Jennifer Woyach, MD - Real-World Challenges and Solutions with BTKi in CLL: Therapeutic Insights for Community Practice - a podcast by PVI, PeerView Institute for Medical Education
from 2023-03-14T18:00
Go online to PeerView.com/DWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. First- and second-generation Bruton tyrosine kinase (BTK) inhibitors have transformed the standard of care in many different chronic lymphocytic leukemia (CLL) settings—from treatment-naïve to relapsed disease, as well as in high-risk settings—but are you prepared to fully integrate established and emerging BTKi options into clinical practice, including in the context of community-based care? Find out by viewing this activity, which highlights the clinical decision-making of an academic and a community specialist. Throughout, the panelists will use a series of real-world cases to demonstrate the practicalities of using modern BTKi therapy, provide guidance on the use of next-generation agents, and offer a strong grounding for updated AE management protocols that can ensure safe delivery of care. Upon completion of this activity, participants should be better able to: Summarize evidence from pivotal clinical trials and practice guidelines on BTK inhibitor efficacy, safety, and mechanistic/selectivity differences, including as single-agent approaches or as part of novel combinations; Recommend personalized BTK inhibitor therapy for patients with treatment-naïve CLL based on prognostic information, the presence of comorbidities, and safety considerations; Select individualized, sequential BTK inhibitor options for the management of patients with relapsed/refractory CLL or for individuals who develop therapeutic intolerance; and Manage adverse events associated with the use of novel targeted approaches with BTK inhibitors in the CLL setting.
Further episodes of PeerView Oncology
Further podcasts by PVI, PeerView Institute for Medical Education